



NeuroTech  
Analytics

# INVESTMENT DIGEST *TEASER*

NeuroTech Industry  
Overview 2021 / Q2

# Table of Contents

<b>Investments in Neurotech Industry</b>	3
Leading Companies by Amount and Stage of Funding	7
Investment Landscape at a Glance	12
<b>Neurotech Industry Landscape / 2020 (Mind Maps)</b>	14
50 Leading Companies in NeuroTech Sector	19
Top-10 Neurotech Companies by Total Investments in 2021	21
<b>50 Leading Investors in Neurotech Sector</b>	24
Neurotech Industry Market Timeline	30
Conclusions	31
<b>Neurotech Publicly Traded Companies</b>	33
Neurotech Market Capitalization	34
Top-10 Neurotech Publicly Traded Companies	36
Main Neurotech IPOs in 2020	38
<b>Conclusions/Key Takeaways</b>	43
<b>Big Data Analytical Dashboards</b>	48
<b>Disclaimer</b>	55

## Neurotech Investment Digest at a Glance

This Investment Digest is summarizing key players and observations in the private equity and venture capital ecosystem, focusing on the neurotech industry. Here we have summarized information about key industry trends, more than 1200 promising neurotech companies, 50 leading investors in this sector, and more than 90 longevity-focused publicly traded corporations, outlining major investment rounds and relevant R&D trends illustrating the industry traction and readiness of institutional investors (big pharma/biotech) to potentially acquire most successful neurotech startups.


Covid pandemic facilitated biotech capital market development in general, although neurotech market cap of publicly traded companies stagnated in the previous year.

3 neurotech companies made IPO in 2020, whereas more than a hundred received private equity funding.

Neurotech is now regularly embraced as a major topic of interest for panel discussions and entire conference series by top-tier finance and business media brands including The Economist, Financial Times and Bloomberg.

As the technology continues to evolve, meeting the needs of the developing market will require dynamic approaches in understanding and delivering the types of goods and services demanded.

# Investments in Neurotech Industry



## Total early stage investments into longevity by 2020: **\$7.3B**

**Neurotech Industry** is one of the most promising and prospective sectors of modern biotech in particular and exponential markets in general.


Corporations, investors and other agents who will be able to utilize this growth and development will gain essential competitive advantages in their struggle for new markets, audiences, funding, and technologies.

That competition is presented by the amounts of investments in new biotech companies. During the last 10 years, amount of investments in Neurotech companies increased in 21 times from \$331 million to \$7.3 billion.

**Overall investments** in the Neurotech companies amounts to \$33.2 billion.


Current report is based on the data of 1200 companies, 100 public and 50 leading investors.

# Top-10 Neurotech Companies by Total Investments in 2021




# Top-10 Countries in Neurotech Sector in 2021

## Amount of funding



## Number of companies



The United States firmly leads in Neurotech Industry as shown by such quantitative indicators as total amount of investments and number of companies operating in the sector. 647 US-based companies have raised more than \$24 billion total funding by the beginning of 2021. Equally as well-known for its strong biomedical community as the US, United Kingdom is the second most invested country with \$1.7B total investments. Other countries with intense focus in Neurotech Industry include Canada, Israel, Germany, Switzerland, France, and others. Europe is the most active region in the sector.

# Investment Landscape at a Glance

As of beginning of 2021, total investments into the Neurotech companies globally had crossed the \$30.7 billion mark, of which \$13.2B were raised in 2020 and 2021.

Some of the major deals included:


- **InSightec** – \$150M earmarked for supporting research to evaluate focused ultrasound for treating essential tremors (Series F round);
- **Locanabio** – \$100M earmarked for treatments aimed at degenerative diseases (Series B round);
- **Annexon Biosciences** – \$100M earmarked to advance broad pipeline of classical complement therapeutics (Series D round);
- **Mindstrong** – \$100M to scale its virtual mental healthcare and digital symptom measurement offering (Series C Round);
- **Taysha Gene Therapies** – \$95M to bolster its initial clinical studies (Series B Round).

## Top-5 Investment deals




# NeuroTech Industry Landscape Overview 2021

Companies - 1200  
Investors - 650  
Hubs - 60



## 1209 Neurotech Companies: Regional Proportion



The US is still firmly in the lead in terms of its proportion of Neurotech companies. With Canada and European countries, they hold 87% of the whole market. Another big part of the market, 8.7%, belongs to Asia. However, Asia-Pacific region has begun to aggressively increase its activity in Neurotech Industry. Now, the most active asian country is Israel with 36 active companies. With Singapore and China, this 3 countries are the leaders of the APAC market.



# Neurotech Industry Market Timeline



# Neurotech Publicly Traded Companies

Cumulative capitalization dynamics, 2020 - 2021



The coronavirus pandemic had a striking effect on publicly traded neurotech companies and caused the declining of the industry by 25%. Despite that, neurotech firms have recovered by the end of 2020.


The majority of the market is represented by old mature healthcare companies which own different divisions with neuroscience as one of them.

The biggest companies by market capitalization are [Medtronic](#), [Boston Scientific](#), [Lundbeck](#), [Biogen](#), [Denali](#), [TerrAscend](#).


Despite the dominance of the mature players, there are 5 young companies which closed IPO successfully in 2020: [Annexon Biosciences](#), [Annovis Bio](#), [Taysha Gene Therapies](#), [Clene Nanomedicine](#), [Synaptogenix](#).

Technologically, publicly traded Neurotech companies are similar to other companies in the sector (which reached series B or C funding rounds), which means that their market capitalization growth can be an approximation of the dynamics of the whole sector.


# Top-20 Neurotech Publicly Traded Companies




## Top-10 Public Companies Involved in the Neurotech Industry by Market Capitalization in 2020




The chart represents the top 10 public companies operating in the Neurotech sector. Most of the companies belong to the healthcare industry with departments or subsidiaries which specialized in Neurotechnologies. Most of the top-tier companies have a large experience in transforming a medical system and innovating new medical solutions. Most of the companies develop innovative pharmaceuticals for people suffering from CNS disorders. However, there are gene therapy providers as well as suppliers of implants.



**Longevity Industry 1.0**  
Defining the Biggest and Most  
Complex Industry in Human History



**Longevity Industry 2.0**  
DeepTech Engineering The Accelerated  
Trajectory of Human Longevity  
The Blueprint and Pathway from 1.0 to 2.0



In this book, Alon Braun covers the main stages of the business journey, the decisions to be taken on the threshold of each one, the difficulties particular to each stage, and the techniques for negotiating them.

The author stresses the necessity to express the ideas to oneself and then the outside world once an idea takes hold. The book aligns the psychology and productivity of starting out entrepreneurs and founders whose company is up and running. The book helps to identify and overcome blind spots at each step.


Alon Braun applies his own expertise in guiding companies on how to grow from an initial idea to profitability and achieve their goals quickly in both the public and the private sectors.

*"My aim is to help you make an impact on the world by showing you how to commercialise your ideas or inspiration and grow a successful business"*

**Alon Braun**



**NEUROTECH  
ANALYTICS**



**Link to the Report: [www.neurotech.com/investment-digest](http://www.neurotech.com/investment-digest)**

**E-mail: [info@neurotech.com](mailto:info@neurotech.com)**

**Website: [www.neurotech.com](http://www.neurotech.com)**

**NeuroTech Analytics (NTA) Disclaimer.**

The information and opinions in this report were prepared by NeuroTech Analytics. The information herein is believed by NTA to be reliable but NA makes no representation as to the accuracy or completeness of such information. There is no guarantee that the views and opinions expressed in this communication will come to pass. NA may provide, may have provided or may seek to provide advisory services to one or more companies mentioned herein. In addition, employees of NTA may have purchased or may purchase securities in one or more companies mentioned in this report. Opinions, estimates and analyses in this report constitute the current judgment of the author as of the date of this report. They do not necessarily reflect the opinions of NTA and are subject to change without notice. NTA has no obligation to update, modify or amend this report or to otherwise notify a reader thereof in the event that any matter stated herein, or any opinion, estimate, forecast or analysis set forth herein, changes or subsequently becomes inaccurate. This report is provided for informational purposes only. It is not to be construed as an offer to buy or sell or a solicitation of an offer to buy or sell any financial instruments or to participate in any particular trading strategy in any jurisdiction.